| Bvf Partners L P/Il |
Non-Executive |
Repare Therapeutics Inc. (RPTX)
|
2023-11-16 |
$5.09 |
-46.0% |
1,227,301
|
$6,249,889 |
| Bvf Partners L P/Il |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2023-11-03 |
$12.80 |
264.0% |
414,105
|
$5,301,325 |
| Bvf Partners L P/Il |
Non-Executive |
Repare Therapeutics Inc. (RPTX)
|
2023-11-02 |
$3.60 |
-23.6% |
783,709
|
$2,821,352 |
| Bvf Partners L P/Il |
Non-Executive Director |
Olema Pharmaceuticals, Inc. (OLMA)
|
2023-09-12 |
$9.84 |
20.2% |
1,505,932
|
$14,818,371 |
| Bvf Partners L P/Il |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2023-01-12 |
$30.51 |
52.7% |
41,007
|
$1,251,191 |
| Bvf Partners L P/Il |
Non-Executive Director |
XOMA Corp (XOMA)
|
2023-01-06 |
$18.91 |
40.8% |
22,249
|
$420,737 |
| Bvf Partners L P/Il |
Non-Executive |
Third Harmonic Bio, Inc. (THRD)
|
2022-12-20 |
$4.11 |
190.1% |
214,063
|
$879,499 |
| Bvf Partners L P/Il |
Non-Executive Director |
Rain Therapeutics Inc. (RAIN)
|
2022-11-08 |
$5.83 |
-79.2% |
1,710,358
|
$9,971,387 |
| Bvf Partners L P/Il |
Non-Executive Director |
XOMA Corp (XOMA)
|
2022-09-27 |
$16.61 |
60.3% |
24,642
|
$409,309 |
| Bvf Partners L P/Il |
Non-Executive Director |
XOMA Corp (XOMA)
|
2022-09-16 |
$17.59 |
51.3% |
56,309
|
$990,718 |
| Bvf Partners L P/Il |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2022-08-22 |
$26.00 |
79.2% |
545,525
|
$14,183,650 |
| Bvf Partners L P/Il |
Non-Executive |
Repare Therapeutics Inc. (RPTX)
|
2022-06-13 |
$12.73 |
-78.4% |
149,161
|
$1,898,820 |
| Bvf Partners L P/Il |
Non-Executive Director |
Olema Pharmaceuticals, Inc. (OLMA)
|
2022-06-10 |
$4.03 |
193.2% |
200,000
|
$806,900 |
| Bvf Partners L P/Il |
Non-Executive |
Repare Therapeutics Inc. (RPTX)
|
2022-06-06 |
$11.90 |
-76.9% |
1,836,958
|
$21,859,329 |
| Bvf Partners L P/Il |
Non-Executive |
Cullinan Oncology, Inc. (CGEM)
|
2022-06-01 |
$11.00 |
63.0% |
751,396
|
$8,264,905 |
| Bvf Partners L P/Il |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2022-05-27 |
$14.34 |
225.0% |
289,426
|
$4,150,321 |
| Bvf Partners L P/Il |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2022-05-20 |
$14.00 |
232.9% |
10,100
|
$141,394 |
| Bvf Partners L P/Il |
Non-Executive |
Repare Therapeutics Inc. (RPTX)
|
2022-05-18 |
$8.50 |
-67.6% |
420,000
|
$3,570,000 |
| Bvf Partners L P/Il |
Non-Executive |
Cullinan Oncology, Inc. (CGEM)
|
2022-05-13 |
$9.07 |
97.7% |
1,109,900
|
$10,063,936 |
| Bvf Partners L P/Il |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2022-05-06 |
$19.46 |
139.4% |
250,000
|
$4,865,365 |
| Bvf Partners L P/Il |
Non-Executive |
Cullinan Oncology, Inc. (CGEM)
|
2022-04-01 |
$10.75 |
66.8% |
276,000
|
$2,966,972 |
| Bvf Partners L P/Il |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2022-01-31 |
$38.96 |
19.6% |
130,309
|
$5,076,473 |
| Bvf Partners L P/Il |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2022-01-24 |
$37.76 |
23.4% |
272,767
|
$10,300,637 |
| Bvf Partners L P/Il |
Non-Executive |
Repare Therapeutics Inc. (RPTX)
|
2022-01-19 |
$14.10 |
-80.5% |
997,961
|
$14,071,250 |
| Bvf Partners L P/Il |
Non-Executive Director |
Rain Therapeutics Inc. (RAIN)
|
2022-01-07 |
$12.00 |
-89.9% |
557,728
|
$6,692,638 |
| Bvf Partners L P/Il |
Non-Executive Director |
Olema Pharmaceuticals, Inc. (OLMA)
|
2021-11-30 |
$9.39 |
26.0% |
739,675
|
$6,945,770 |
| Bvf Partners L P/Il |
Non-Executive Director |
Rain Therapeutics Inc. (RAIN)
|
2021-09-21 |
$13.94 |
-91.3% |
11,033
|
$153,829 |
| Bvf Partners L P/Il |
Non-Executive Director |
Rain Therapeutics Inc. (RAIN)
|
2021-09-13 |
$16.49 |
-92.7% |
392,269
|
$6,468,516 |
| Bvf Partners L P/Il |
Non-Executive Director |
Rain Therapeutics Inc. (RAIN)
|
2021-07-06 |
$15.47 |
-92.2% |
587,002
|
$9,078,692 |
| Bvf Partners L P/Il |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2021-07-01 |
$47.00 |
-0.9% |
544,166
|
$25,575,802 |
| Bvf Partners L P/Il |
Non-Executive Director |
Rain Therapeutics Inc. (RAIN)
|
2021-05-24 |
$15.94 |
-92.4% |
123,347
|
$1,966,334 |
| Bvf Partners L P/Il |
Non-Executive Director |
Rain Therapeutics Inc. (RAIN)
|
2021-05-19 |
$16.59 |
-92.7% |
208,465
|
$3,457,720 |
| Bvf Partners L P/Il |
Non-Executive Director |
Rain Therapeutics Inc. (RAIN)
|
2021-05-13 |
$14.26 |
-91.5% |
58,000
|
$827,167 |
| Bvf Partners L P/Il |
Non-Executive Director |
CTI BIOPHARMA CORP (CTIC)
|
2021-04-01 |
$2.50 |
263.6% |
2,000,000
|
$5,000,000 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2021-03-30 |
$19.75 |
155.0% |
300,000
|
$5,925,000 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2021-03-22 |
$22.75 |
121.4% |
79,500
|
$1,808,625 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2021-03-16 |
$23.00 |
119.0% |
250,000
|
$5,749,900 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2021-01-21 |
$24.75 |
103.5% |
844,680
|
$20,905,830 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2020-12-18 |
$16.05 |
213.8% |
160,000
|
$2,568,000 |
| Bvf Partners L P/Il |
Non-Executive Director |
Olema Pharmaceuticals, Inc. (OLMA)
|
2020-11-19 |
$19.00 |
-37.7% |
1,135,334
|
$21,571,346 |
| Bvf Partners L P/Il |
Non-Executive |
GLYCOMIMETICS INC (GLYC)
|
2020-11-04 |
$2.60 |
-93.7% |
1,266,737
|
$3,293,516 |
| Bvf Partners L P/Il |
Non-Executive |
GLYCOMIMETICS INC (GLYC)
|
2020-10-30 |
$2.75 |
-94.0% |
932,612
|
$2,564,683 |
| Bvf Partners L P/Il |
Non-Executive Director |
XOMA Corp (XOMA)
|
2020-09-23 |
$18.34 |
45.2% |
51,368
|
$941,963 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2020-09-15 |
$11.75 |
328.7% |
146,754
|
$1,724,360 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2020-09-10 |
$11.10 |
353.9% |
189,651
|
$2,104,785 |
| Bvf Partners L P/Il |
Non-Executive Director |
XOMA Corp (XOMA)
|
2020-09-04 |
$18.77 |
41.8% |
7,737
|
$145,228 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2020-09-03 |
$11.17 |
350.9% |
201,906
|
$2,255,290 |
| Bvf Partners L P/Il |
Non-Executive Director |
XOMA Corp (XOMA)
|
2020-09-01 |
$18.71 |
42.3% |
35,621
|
$666,484 |
| Bvf Partners L P/Il |
Non-Executive Director |
XOMA Corp (XOMA)
|
2020-08-25 |
$19.40 |
37.2% |
28,175
|
$546,650 |
| Bvf Partners L P/Il |
Non-Executive |
XOMA Corp (XOMA)
|
2020-08-20 |
$19.47 |
36.7% |
6,163
|
$120,004 |
| Bvf Partners L P/Il |
Non-Executive |
XOMA Corp (XOMA)
|
2020-08-14 |
$18.46 |
44.2% |
27,022
|
$498,736 |
| Bvf Partners L P/Il |
Non-Executive |
IDEAYA Biosciences, Inc. (IDYA)
|
2020-06-30 |
$13.32 |
180.6% |
2,531
|
$33,704 |
| Bvf Partners L P/Il |
Non-Executive |
IDEAYA Biosciences, Inc. (IDYA)
|
2020-06-22 |
$14.31 |
161.1% |
117,996
|
$1,688,929 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2020-06-08 |
$15.20 |
231.4% |
87,254
|
$1,326,261 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2020-06-01 |
$14.00 |
259.8% |
1,462,510
|
$20,475,140 |
| Bvf Partners L P/Il |
Non-Executive |
XOMA Corp (XOMA)
|
2020-03-25 |
$17.20 |
54.8% |
8,264
|
$142,129 |
| Bvf Partners L P/Il |
Non-Executive |
XOMA Corp (XOMA)
|
2020-03-18 |
$14.52 |
83.3% |
4,439
|
$64,475 |
| Bvf Partners L P/Il |
Non-Executive |
XOMA Corp (XOMA)
|
2020-03-17 |
$17.94 |
48.4% |
118,277
|
$2,121,654 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2020-01-16 |
$16.15 |
211.9% |
278,730
|
$4,501,490 |
| Bvf Partners L P/Il |
Non-Executive |
Merus N.V. (MRUS)
|
2020-01-13 |
$14.98 |
236.3% |
83,962
|
$1,257,616 |
|
|
|
|
|
Return |
Profit / (loss) |
Cost |
|
|
|
Total |
|
44.7% |
$141,612,536 |
$316,501,998 |